Tag
The PRABITAS trial demonstrated that a 14-day trifluridine-tipiracil plus bevacizumab regimen is non-inferior to the conventional 28-day schedule in refractory metastatic colorectal cancer, with significantly reduced hematological and gastr
This study assesses the efficacy and safety of pembrolizumab combined with bevacizumab and oral metronomic cyclophosphamide in heavily pretreated platinum-resistant ovarian cancer patients, showing modest disease control with manageable tox
A double-blind randomized trial found that a single intraoperative intravitreal bevacizumab injection improved 3-year trabeculectomy survival and reduced postoperative medication needs versus placebo.
A nationwide Japanese real-world study suggests that a defined body surface area–adjusted bevacizumab exposure range may improve progression-free and overall survival in unresectable HCC treated with atezolizumab plus bevacizumab, without i
The GASTO-1053 phase II study demonstrates that combining bevacizumab with fractionated stereotactic radiotherapy significantly improves intracranial progression-free survival (18.3 months) and quality of life for NSCLC patients with extens
Two randomized phase III trials tested adding atezolizumab to bevacizumab plus chemotherapy in recurrent ovarian cancer. Neither AGO‑OVAR 2.29/ENGOT‑ov34 (non‑platinum, platinum‑resistant) nor ATALANTE/ENGOT‑ov29 (platinum‑sensitive) met th
Phase 3 TALENTop trial interim results show liver resection following atezolizumab plus bevacizumab induction significantly prolongs time to treatment failure in advanced HCC without extrahepatic spread.
A recent phase II trial demonstrates lenvatinib’s efficacy and manageable safety as a second-line treatment for unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.
The U-BOMB phase 2 trial demonstrates that the combination of utidelone and bevacizumab shows encouraging efficacy and tolerability in patients with ERBB2-negative metastatic breast cancer and active brain metastases, addressing a critical
HER2 amplification/mutation in RAS/BRAF wild-type metastatic colorectal cancer is a negative prognostic factor but does not predict differential benefit from bevacizumab or anti-EGFR therapies, based on analysis of 1,604 patients across eig
The HEPATORCH phase 3 trial demonstrates that toripalimab plus bevacizumab significantly improves survival outcomes versus sorafenib in previously untreated advanced hepatocellular carcinoma, with manageable safety.
A phase 2 study shows that bevacizumab and erlotinib combination therapy offers notable tumor responses and survival benefits in both hereditary and sporadic papillary renal-cell carcinoma, with manageable toxicity.
